Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Shares Outstanding: 2019-2025

Historic Shares Outstanding for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $101.4 million.

  • Beam Therapeutics' Shares Outstanding rose 22.77% to $101.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.4 million, marking a year-over-year increase of 22.77%. This contributed to the annual value of $83.6 million for FY2024, which is 2.45% up from last year.
  • Latest data reveals that Beam Therapeutics reported Shares Outstanding of $101.4 million as of Q3 2025, which was up 0.60% from $100.8 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Shares Outstanding high stood at $101.4 million for Q3 2025, and its period low was $61.7 million during Q1 2021.
  • Over the past 3 years, Beam Therapeutics' median Shares Outstanding value was $82.4 million (recorded in 2024), while the average stood at $86.1 million.
  • Data for Beam Therapeutics' Shares Outstanding shows a peak YoY surged of 34.29% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Beam Therapeutics' Shares Outstanding stood at $68.4 million in 2021, then rose by 4.22% to $71.3 million in 2022, then climbed by 14.53% to $81.6 million in 2023, then rose by 2.45% to $83.6 million in 2024, then rose by 22.77% to $101.4 million in 2025.
  • Its last three reported values are $101.4 million in Q3 2025, $100.8 million for Q2 2025, and $100.6 million during Q1 2025.